Drug Profile


Alternative Names: HCM 1; MYK-461; SAR-439152

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MyoKardia
  • Class Cardiovascular therapies; Small molecules
  • Mechanism of Action Myosin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypertrophic cardiomyopathy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypertrophic cardiomyopathy

Most Recent Events

  • 15 Nov 2017 Pharmacodynamics data from a preclinical trial in Hypertrophic cardiomyopathy released by MyoKardia
  • 05 Oct 2017 Chemical structure information added
  • 18 Sep 2017 Updated adverse events and efficacy data from the phase-II PIONEER-HCM clinical trial in Hypertrophic cardiomyopathy released by MyoKardia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top